Algorae Pharmaceuticals Limited (ASX:1AIO)

Australia · Delayed Price · Currency is AUD · Option

0.0010

0.00 (0.00%)

At close: Mar 25, 2026

-50.00% (1Y)

Market Cap	16.03M -5.0%
Revenue (ttm)	n/a
Net Income	-802.96K
EPS	-0.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,642,903
Open	0.0010
Previous Close	0.0010
Day's Range	0.0010 - 0.0010
52-Week Range	0.0010 - 0.0070
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 24, 2025

About Algorae Pharmaceuticals

Algorae Pharmaceuticals Limited, a pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand. The company’s product pipeline includes AI-116, a novel combination drug candidate made up of donepezil and cannabidiol for the treatment of dementia, including Alzheimer’s disease; AI-168, a novel combination drug candidate made up of a cannabinoid and an off-patent pharmaceutical ingredient for the treatment of cardiovascular disease, such as hypertension; and NTCELL, an alginate... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 1987

Employees 48

Stock Exchange Australian Securities Exchange

Ticker Symbol 1AIO

Full Company Profile